These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 35220259)

  • 1. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
    Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM;
    Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
    Huang CH; Ju JS; Chiu TH; Huang AC; Tung PH; Wang CC; Liu CY; Chung FT; Fang YF; Guo YK; Kuo CS; Yang CT
    Int J Cancer; 2022 Feb; 150(4):626-635. PubMed ID: 34558665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
    Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
    Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
    Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
    Masood A; Kancha RK; Subramanian J
    Semin Oncol; 2019 Jun; 46(3):271-283. PubMed ID: 31558282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
    Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
    Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
    Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT
    Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
    Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES
    J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
    Pang LL; Gan JD; Tan JR; Huang YH; Liao J; Liang WT; Deng PB; Fang WF
    Cancer; 2022 Nov; 128(21):3804-3814. PubMed ID: 36069292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Popat S; Hsia TC; Hung JY; Jung HA; Shih JY; Park CK; Lee SH; Okamoto T; Ahn HK; Lee YC; Sato Y; Lee SS; Mascaux C; Daoud H; Märten A; Miura S
    Oncologist; 2022 Apr; 27(4):255-265. PubMed ID: 35274704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
    Sehgal K; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
    Oncologist; 2021 Apr; 26(4):281-287. PubMed ID: 32969527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
    Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.
    Sonehara K; Kobayashi T; Tateishi K; Morozumi N; Yoshiike F; Hachiya T; Ono Y; Takasuna K; Agatsuma T; Masubuchi T; Matsuo A; Tanaka H; Morikawa A; Hanaoka M; Koizumi T
    Thorac Cancer; 2019 May; 10(5):1078-1085. PubMed ID: 31006178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.
    Ullas B; Shrinidhi N; Mansi S; Narayan S; Parveen J; Surender D; Joslia JT; Anurag M
    J Cancer Res Clin Oncol; 2023 Apr; 149(4):1541-1549. PubMed ID: 35581383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
    Han C; Ding X; Li M; Luo N; Qi Y; Wang C
    J Cancer Res Clin Oncol; 2022 May; 148(5):1265-1268. PubMed ID: 35230510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
    Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
    Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
    BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.